Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: A Children's Oncology Group report

Leukemia

Volumn 27, Issue 5, 2013, Pages 1174-1177

  Goldman, S ^a   Smith, L ^b   Anderson, J R ^b   Perkins, S ^c   Harrison, L ^d   Geyer, M B ^e   Gross, T G ^f   Weinstein, H ^e   Bergeron, S ^g   Shiramizu, B ^h   Sanger, W ⁱ   Barth, M ^j   Zhi, J ^k   Cairo, M S ^d  

^a Medical City Children's Hospital   (United States)

^b UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^h UNIVERSITY OF HAWAII   (United States)

ⁱ UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^j ROSWELL PARK CANCER INSTITUTE   (United States)

^k HOFFMANN LA ROCHE INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE; VINCRISTINE SULFATE;

ADULT; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CHILD; CLINICAL ARTICLE; FEMALE; HUMAN; INFECTION; LARGE CELL LYMPHOMA; LETTER; MALE; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PAIN; PRIORITY JOURNAL; STEVENS JOHNSON SYNDROME; STOMATITIS; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; INFANT; LYMPHOMA, B-CELL; MALE; METHOTREXATE; NEOPLASM STAGING; PREDNISONE; VINCRISTINE;

EID: 84877619828     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.255     Document Type: Letter

References (13)

1. Meinhardt A, Burkhardt B, Zimmermann M, Borkhardt A, Kontny U, Klingebiel T et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol 2010; 28: 3115-3121.
2. Murphy SB. Classification, staging and end results of treatment of childhood non- Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol 1980; 7: 332-339.
3. Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non- Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 2007; 109: 2773-2780.
4. Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J et al. Results of a randomized international study of high-risk central nervous system B non- Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007; 109: 2736-2743.
5. Shiramizu B, Goldman S, Kusao I, Agsalda M, Lynch J, Smith L et al. Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage III/IV) B-cell non-Hodgkin lymphoma: a children's oncology group report. Br J Haematol 2011; 153: 758-763.
6. Griffin TC, Weitzman S, Weinstein H, Chang M, Cairo M, Hutchison R et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer 2009; 52: 177-181.
7. Zwick C, Murawski N, Pfreundschuh M. Rituximab in high-grade lymphoma. Semin Hematol 2010; 47: 148-155.
8. Greenwood M. A Report on the Natural Duration of Cancer. Her Majesty's Stationary Office: London, UK, 1929.
9. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
10. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIVnegative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113: 4834-4840.
11. He YF, Li YH, Wang FH, Jiang WQ, Xu RH, Sun XF et al. The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma. Ann Hematol 2008; 87: 481-485.
12. Cairo MS, Sposto R, Gerrard M, Auperin A, Goldman SC, Harrison L et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (415 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study. J Clin Oncol 2012; 30: 387-393.
13. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010; 116: 2040-2045.